Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines
Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines
复制标题
DOI:
10.1093/protein/gzu020
复制
发表时间:
2014-07-01
影响因子:
2.4
通讯作者:
Petrenko, Valery A.
中科院分区:
文献类型:
--
作者:
Bedi, Deepa;Gillespie, James W.;Petrenko, Valery A.
It is hypothesized that the use of targeted drug delivery systems can significantly improve the therapeutic index of small molecule chemotherapies by enhancing accumulation of the drugs at the site of disease. Phage display offers a high-throughput approach for selection of the targeting ligands. We have successfully isolated phage fusion proteins selective and specific for PANC-1 pancreatic cancer cells. Doxorubicin liposomes (Lipodox) modified with tumor-specific phage fusion proteins enhanced doxorubicin uptake specifically in PANC-1 cells as compared with unmodified Lipodox and also compared with normal breast epithelial cells. Phage protein-targeted Lipodox substantially increased the concentration of doxorubicin in the nuclei of PANC-1 cells in spite of P-glycoprotein-mediated drug efflux. The in vitro cytotoxic activity obtained with pancreatic cell-targeted Lipodox was greater than that of unmodified Lipodox. We present a novel and straightforward method for preparing pancreatic tumor-targeted nanomedicines by anchoring pancreatic cancer-specific phage proteins within the liposome bilayer.